3-chloro-4-fluoro-N-ethylbenzamide | 1067637-34-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-chloro-4-fluoro-N-ethylbenzamide
• 英文别名: 4-ethylcarbamoyl-2-chloro-1-fluorobenzene；3-chloro-N-ethyl-4-fluorobenzamide
• CAS: 1067637-34-6
• 化学式: C₉H₉ClFNO
• 分子量: 201.628
• InChiKey: FQAWCBBESHVGCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-chloro-4-fluoro-N-ethylbenzamide 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 二甲基亚砜 、 1,2-二氯乙烷 为溶剂， 反应 86.0h， 生成 3-chloro-N-ethyl-4-(4-((2-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)methyl)piperazin-1-yl)benzamide
  参考文献：
  名称：

  Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors

  摘要：

  Structure based drug design of a series of novel 1,4-benzoxazin-3-one derived PARP-1 inhibitors are described. The synthesis, enzymatic 82 cellular activities and pharmacodynamic effects are described. Optimized analogs demonstrated inhibition of poly-ADP-ribosylation in SW620 tumor bearing nude mice through 24 h following a single dose. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.055
• 作为产物：
  描述：

  3-氯-4-氟苯甲酸 、 乙胺盐酸盐 在 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以77%的产率得到3-chloro-4-fluoro-N-ethylbenzamide
  参考文献：
  名称：

  Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors

  摘要：

  Structure based drug design of a series of novel 1,4-benzoxazin-3-one derived PARP-1 inhibitors are described. The synthesis, enzymatic 82 cellular activities and pharmacodynamic effects are described. Optimized analogs demonstrated inhibition of poly-ADP-ribosylation in SW620 tumor bearing nude mice through 24 h following a single dose. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.055

文献信息

• Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
  申请人：Gangloff Anthony R.

  公开号：US20100190763A1

  公开（公告）日：2010-07-29

  Disclosed are compounds of the following formula: in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

  披露了以下公式的化合物： 其中R1、R2、R3、R4、R5、R6、R7、X和t在规范中定义。还披露了含有这些化合物的药物组合物、试剂盒和制造物品，以及用于制备这些化合物的方法和中间体，以及使用这些化合物治疗与PARP活性相关的疾病、紊乱和状况的方法。
• [EN] Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS<br/>[FR] INHIBITEURS DE LA POLY (ADP-RIBOSE) POLYMÉRASE (PARP)
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2011014681A1

  公开（公告）日：2011-02-03

  Compounds of the following formula are provided for use with PARP: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits, and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds.

  提供以下公式的化合物供PARP使用：其中变量如本文所定义。还提供包括这些化合物的药物组合物、试剂盒和制造品，制备这些化合物有用的方法和中间体，以及使用这些化合物的方法。
• HETEROARYL DERIVATIVES
  申请人：Matsuoka Masato

  公开号：US20100048537A1

  公开（公告）日：2010-02-25

  The present invention relates to a compound represented by formula [1] or a pharmaceutically acceptable salt thereof: In formula [1], one of X and Y is CH and the other is oxygen or sulfur; R is hydrogen, etc.; Z is hydrogen, etc.; Ar is phenyl, etc.; and n is 1 or 2 and or m is 1 or 2, excluding compounds where n is 2 and m is 2 simultaneously. Also provided is a pharmaceutical composition comprising a compound of formula [1] or a pharmaceutically acceptable salt thereof as an active ingredient. The composition is usable as an agent for the prevention or treatment of depression, panic disorder, anxiety, obsessive-compulsive disorder, chronic pain, fibromyalgia, obesity, stress urinary incontinence, and overactive bladder.

  本发明涉及一种由公式[1]表示的化合物或其药学上可接受的盐： 在公式[1]中，X和Y中的一个是CH，另一个是氧或硫；R是氢等；Z是氢等；Ar是苯等；n为1或2，m为1或2，不包括n为2且m为2的化合物。还提供了一种药物组合物，其包括公式[1]的化合物或其药学上可接受的盐作为活性成分。该组合物可作为预防或治疗抑郁症、惊恐障碍、焦虑症、强迫症、慢性疼痛、纤维肌痛、肥胖症、压力性尿失禁和过度活动膀胱的药物。
• Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS
  申请人：Gangloff Anthony R.

  公开号：US20110158989A1

  公开（公告）日：2011-06-30

  Disclosed are compounds of the following formula: in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

  本发明涉及以下式的化合物：其中R1，R2，R3，R4，R5，R6，R7，X和t在规范中定义。本发明还涉及含有这些化合物的制药组合物、工具箱和制造物品、制备这些化合物有用的中间体和方法，以及使用这些化合物治疗与PARP活性相关的疾病、障碍和病况的方法。
• Substituted 7,8,9,10-tetrahydro-5H-dipyrido[1,2-a:3′,2′-e]pyrazin-6(6aH)-ones
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US08124606B2

  公开（公告）日：2012-02-28

  Disclosed are compounds of the following formula: in which R1, R2, R5, R6, R7, R11, X, and m are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

  本发明公开了以下式子的化合物：其中R1、R2、R5、R6、R7、R11、X和m在说明书中有定义。本发明还公开了含有该化合物的制药组合物、试剂盒和制造物品，以及制备该化合物有用的中间体和方法，以及使用该化合物治疗与PARP活性相关的疾病、疾病和病症的方法。